Wockhardt

Indian markets showed volatility on May 5 amid escalating US-Iran tensions. The Nifty 50 ended up 0.36%, while the Sensex declined 0.33%. Notable gainers included CreditAccess Grameen and Wockhardt, though profit-taking led to losses in several other stocks.

Wockhardt's shares surged 12.55% to ₹ 1,604 following a profitable Q4FY26 with a net profit of ₹ 164 crore. Strong revenue growth from biotech and emerging markets fueled performance, with full-year revenue rising to ₹ 3,373 crore and EBITDA increasing by 51%.

Buy or sell: Ganesh Dongre recommends three stocks to buy on Monday — Wockhardt, LT, and HDFC Bank.

Following a repo rate cut by the RBI, the Indian stock market saw renewed optimism, with Nifty 50 and Sensex gaining. Key sectors like PSU Banks and IT led the rally, despite mixed performance in broader markets.

Wockhardt's share price surged 6.5% following FDA acceptance of its New Drug Application for Zaynich, marking a significant milestone for Indian pharma. The two-day rally reached nearly 27%, reflecting renewed investor interest and highlighting India's potential in global antibiotic innovation.

Indian stocks declined on December 01 after reaching highs, influenced by a record low rupee against the dollar and foreign investor selling. The Nifty 50 fell 150 points, closing at 26,175, while the Sensex dropped 531 points to 85,625.

Wockhardt's shares jumped 19.3% to ₹ 1,473 following the US FDA's acceptance of its antibiotic drug Zaynich's New Drug Application. The pharma shares have remained under pressure since hitting a one-year high in July 2025 and have so far lost 22% of their value.

Regarding intraday stocks for today, Vaishali Parekh of Prabhudas Lilladher recommends three stocks to buy: Wockhardt, Gabriel India and Medico Remedies.